Last updated 2026-07-24
TL;DR
Sermorelin has real FDA history (it was sold as Geref before the maker discontinued it commercially). Tesamorelin is FDA-approved, but only for HIV-related lipodystrophy. CJC-1295 and ipamorelin have no FDA approval for any use and are typically sold as research chemicals. All four raise growth hormone by acting on the GHRH pathway or a ghrelin-mimetic pathway, but they differ a lot in half-life, evidence quality, and legal status.
What is the actual difference between CJC-1295, sermorelin, ipamorelin, and tesamorelin?
All four are peptides that push the pituitary to release more growth hormone, but they don't do it the same way or with the same regulatory backing. Sermorelin is a 29-amino-acid fragment of growth hormone-releasing hormone (GHRH). It's the shortest fully active piece of natural GHRH, and it was actually an FDA-approved drug for years under the brand name Geref, used to test pituitary GH reserve and to treat GH deficiency in children. The manufacturer discontinued Geref for business reasons in the mid-2000s, not because of a safety recall. That gives sermorelin a regulatory paper trail that none of the other three peptides in this comparison have. [1] [2] CJC-1295 is a modified, longer-acting GHRH analog. There are two versions people mean when they say the name: CJC-1295 with DAC (Drug Affinity Complex, which binds serum albumin and stretches its half-life to days) and CJC-1295 without DAC, which is chemically almost identical to another peptide called Mod GRF 1-29. Neither version has FDA approval for any use. [3] Ipamorelin is not a GHRH analog at all. It's a ghrelin-receptor agonist, a growth hormone secretagogue that works through a different pituitary pathway. It's often paired with CJC-1295 in compounding pharmacies and research-chemical listings because the two work on separate receptors and are thought to have an additive effect. Ipamorelin has no FDA approval either. Tesamorelin is also a GHRH analog, but it's the one member of this group with a genuine FDA approval, brand name Egrifta, for a specific and narrow indication: reduction of excess abdominal fat in HIV patients with lipodystrophy. It is not approved for general anti-aging use, bodybuilding, or age-related GH decline. [4]
Sermorelin vs HGH: which one should you actually consider?
This is the question most people researching sermorelin actually want answered, so here it is straight: sermorelin is a weaker, indirect way to raise growth hormone, and HGH (recombinant human growth hormone, like Genotropin or Norditropin) is the direct, stronger, faster-acting option. Neither is automatically the 'better' choice; it depends on what's actually wrong and what you're willing to accept. HGH injections put growth hormone itself directly into your bloodstream. Approved uses are specific: adult growth hormone deficiency (confirmed by blood testing, usually a GH stimulation test), pediatric growth failure, and a handful of other confirmed-deficiency conditions. The FDA has never approved HGH for anti-aging, general fatigue, or athletic performance in people with normal GH levels. [5] Sermorelin instead stimulates your own pituitary to make and release GH in a pattern closer to its natural pulsatile rhythm. Because it depends on a working pituitary gland, it doesn't work in someone whose pituitary is severely damaged or nonfunctional. It's also much less potent per dose than injecting HGH directly. If your pituitary is largely intact, this can be an advantage: your body still controls its own feedback loops, and the risk of definitively overshooting GH levels is lower than with exogenous HGH. Sermorelin's downside is real: less clinical trial volume behind current compounded versions, a slower and gentler effect, and it flatly does not work if the underlying problem is pituitary failure rather than reduced GHRH signal. If a prescriber's workup shows true pituitary damage, sermorelin monotherapy is probably the wrong tool. HGH is the direct fix in that case. For someone with mild, age-related decline in GH pulsatility and an intact pituitary, sermorelin is a reasonable, lower-intensity starting point that a prescriber can titrate carefully. It is not a proven anti-aging therapy, and nobody should expect the muscle-and-fat-loss transformation sometimes implied in marketing. For a full breakdown of dosing patterns, see the sermorelin dosage chart and, for the base mechanism and evidence, sermorelin.
How do these four peptides compare on FDA status and evidence quality?
This is the sharpest differentiator between the four, and it's not close.
| Peptide | FDA status | Brand name (if any) | Approved indication | |
|---|---|---|---|---|
| Sermorelin | Formerly approved, discontinued commercially | Geref | GH deficiency diagnosis/treatment (historical) | |
| Tesamorelin | Currently approved | Egrifta | HIV-associated lipodystrophy only | |
| CJC-1295 | Never approved | None | None; sold as research chemical | |
| Ipamorelin | Never approved | None | None; sold as research chemical | Geref's FDA approval history matters because it means sermorelin's basic pharmacology, dosing range, and short-term safety profile were reviewed by the agency at some point, even though the specific commercial product is gone and current sermorelin is compounded rather than FDA-manufactured. [1] [2] Tesamorelin's approval is narrow but real. The FDA-approved labeling is specific to reducing visceral fat in HIV-associated lipodystrophy, based on trials showing measurable reduction in visceral adipose tissue. It says nothing about general fat loss or anti-aging use in HIV-negative adults. [4] CJC-1295 and ipamorelin sit outside FDA oversight entirely. They're commonly labeled 'for research use only, not for human consumption' when sold, which is a legal fig leaf, not a safety endorsement. That doesn't automatically mean they're dangerous, but it does mean there's no FDA-reviewed human dosing data, no standardized manufacturing quality requirement, and no formal post-market safety monitoring. [3] |
What does each peptide actually do to growth hormone levels?
Mechanistically, sermorelin, CJC-1295, and tesamorelin all bind the GHRH receptor on the pituitary and trigger GH release along with a rise in IGF-1 over time. Ipamorelin works differently, binding the ghrelin receptor (also called the growth hormone secretagogue receptor). Sermorelin has a short half-life, roughly 10-20 minutes in circulation, which is why it's typically dosed as a daily subcutaneous injection, usually at night to mimic the body's natural largest GH pulse during early sleep. [1] CJC-1295 with DAC has a dramatically longer half-life, cited in pharmacology literature as approximately 6-8 days, because the DAC portion binds to albumin and resists breakdown. That means far less frequent dosing (sometimes weekly) but also far less control if a problem arises, since the drug lingers in your system for over a week. [3] Ipamorelin has a short half-life similar to sermorelin, roughly 2 hours, and is prized in the unregulated peptide space for being more 'selective', meaning it triggers GH release without significantly raising cortisol or prolactin the way older secretagogues did in early studies. Tesamorelin's half-life is short too, and its clinical trials used daily subcutaneous dosing (2 mg per day is the approved regimen for Egrifta), which is why the approval is specifically for a maintained daily-injection therapy rather than a periodic one. [4]
How are these peptides typically dosed, and how does that compare?
Dosing conventions differ sharply, and part of that difference reflects how much real trial data backs each one versus how much is compounding-pharmacy or gray-market convention. Sermorelin: compounded sermorelin is generally dosed in the 200-300 mcg range subcutaneously at bedtime for adults, based on protocols descended from the original Geref labeling and adapted by prescribers. Dosing should be individualized by a provider based on labs and response; see the sermorelin dosage chart and sermorelin dosage calculator for typical ranges. Tesamorelin: the approved Egrifta dose is 2 mg by subcutaneous injection once daily, per FDA labeling, with no dose titration built into the standard regimen. [4] CJC-1295 and ipamorelin: because neither has FDA-reviewed dosing, quoted amounts (commonly 100 mcg of ipamorelin and 100-300 mcg of CJC-1295, several times weekly or daily depending on the DAC form) come from compounding pharmacy convention and online peptide-community consensus, not from controlled trials with dose-response data published in a way the FDA has reviewed. Treat those numbers as informal, not clinically validated. A prescriber-supervised sermorelin protocol has an advantage here that shouldn't be undersold: because sermorelin has decades of GHRH pharmacology behind it (even if the specific commercial product is gone), a doctor has a much better evidence base to titrate your dose against labs (IGF-1, GH stimulation testing) than they do for CJC-1295 or ipamorelin.
What are the safety differences between these four peptides?
None of these four is risk-free, and the honest safety comparison runs roughly from 'FDA-reviewed adverse event data exists' to 'we're mostly relying on anecdote.' Sermorelin's historical FDA-reviewed adverse effects (from the Geref era and subsequent studies) include injection site reactions, flushing, headache, and rarely dizziness. Because it works through the body's own feedback loop, the risk of significantly elevated IGF-1 is generally considered lower than with direct HGH injection, though it's not zero, especially with off-label overdosing. [1] [2] For more detail on what's known and unknown longer-term, see sermorelin long-term side effects. Tesamorelin's FDA label documents specific adverse events from its trials, including injection site reactions, joint pain (arthralgia), swelling (edema), and a notable finding: tesamorelin can raise blood glucose and has a labeled warning about worsening glucose control, which is why it's monitored carefully in HIV patients, many of whom already have metabolic risk factors. [4] CJC-1295 (particularly the DAC version) carries a theoretical concern that's taken seriously by some endocrinologists: a peptide that sits in circulation for a week or more, continuously stimulating GH release, doesn't allow the body's natural negative feedback pulsing to reset the way short-acting GHRH analogs do. Reported side effects in gray-market use include water retention, joint pain, and injection site problems, but there's no FDA-monitored adverse event reporting system tracking this systematically. [3] Ipamorelin's short half-life and receptor selectivity mean it's generally reported as having fewer side effects related to cortisol or prolactin than older secretagogues, but again, this comes from limited academic study, not large-scale monitored trials. Across all four, the biggest safety variable in practice is sourcing quality, not the molecule itself. Peptides bought from unregulated online sellers can have incorrect concentration, contamination, or mislabeling, since they aren't manufactured under FDA drug-manufacturing oversight. [6]
Is CJC-1295 or ipamorelin legal to buy and use?
This is murkier than most sellers let on. Neither CJC-1295 nor ipamorelin is FDA-approved for any human use, and both are commonly sold under 'research use only' labeling, which legally means they are not supposed to be sold for human consumption. [3] That's different from being a scheduled controlled substance; they aren't classified that way. But it does mean that a seller marketing them for personal injection while labeling them 'research use only' is operating in a legal gray zone, and there's no FDA oversight of manufacturing purity or dosing accuracy for those specific listings. The FDA has separately taken enforcement action against firms selling unapproved peptide products marketed with unproven claims. Sermorelin and tesamorelin, in contrast, can be legally prescribed and dispensed through licensed pharmacies (compounding pharmacies for sermorelin, and standard pharmacy channels for Egrifta) with a valid prescription from a licensed provider, which is a meaningfully different legal footing than a research-chemical purchase.
How do costs compare across sermorelin, CJC-1295, ipamorelin, and tesamorelin?
Cost data is inconsistent across the industry because most of these are compounded or gray-market products without a fixed national price, but general patterns hold. Sermorelin through a compounding pharmacy typically runs in the range of $150-300 per month, depending on dose and pharmacy, according to patient-reported ranges commonly cited by telehealth GH-therapy clinics. Tesamorelin (Egrifta) is dramatically more expensive because it's a brand-name FDA-approved biologic; list prices have been reported in the range of several thousand dollars per month, though insurance coverage for the HIV lipodystrophy indication can offset this substantially for eligible patients. [4] CJC-1295 and ipamorelin, bought online as research chemicals, are often cheaper per vial ($40-100 range is commonly advertised) but that price doesn't include any of the compounding pharmacy quality assurance, prescriber oversight, or dosing guidance that comes with a legitimate prescription pathway, so the sticker price isn't a fair apples-to-apples comparison.
Which peptide is right for which goal?
The honest answer depends on what's actually driving the interest, and a prescriber working from real labs is the only way to answer it responsibly. But here's the general shape of how these four map to different situations. If a GH stimulation test or IGF-1 level suggests mild-to-moderate reduced GH output with an intact pituitary, sermorelin is a defensible, lower-intensity starting therapy with real (if dated) regulatory history behind its core pharmacology. If the goal is treating HIV-associated abdominal fat accumulation specifically, tesamorelin is the only one of these four with an FDA approval for that exact problem, and it should be pursued through a physician managing HIV care, with glucose monitoring given its labeled effect on blood sugar. [4] If someone is being offered CJC-1295 or ipamorelin, generally for muscle gain, fat loss, or 'anti-aging' framing outside a diagnosed medical condition, they should know they're using compounds with no FDA approval, no standardized dosing evidence, and no long-term safety monitoring, regardless of how confidently they're marketed online. If a pituitary workup shows genuinely low GH reserve that doesn't respond to GHRH-based stimulation, none of these four peptides is the right tool. Direct recombinant HGH, prescribed and monitored by an endocrinologist, is the appropriate next step, not a stronger secretagogue.
Can these peptides be combined, and does that change anything?
CJC-1295 and ipamorelin are frequently sold and used together, on the logic that a GHRH analog (CJC-1295) and a ghrelin-receptor agonist (ipamorelin) hit two separate GH-release pathways and may have an additive effect on pulse amplitude. This combination logic has some basis in receptor pharmacology, but combining two unapproved peptides doesn't create a combined safety or efficacy dataset; it just stacks two sets of unknowns. [3] Sermorelin is not typically combined with ipamorelin in mainstream prescriber practice, partly because sermorelin protocols are usually run through licensed telehealth or endocrinology channels that stick to the single, better-documented compound rather than adding an unapproved secretagogue on top. Tesamorelin is not combined with the others in any studied protocol; its trials and label reflect monotherapy dosing only. [4]
Frequently asked questions
Is sermorelin the same as HGH?
No. HGH is growth hormone itself, injected directly. Sermorelin is a GHRH fragment that signals your own pituitary to make and release GH. Sermorelin only works if your pituitary can still respond; HGH works regardless, because it bypasses that step entirely.
Was sermorelin banned by the FDA?
No. The branded version, Geref, was discontinued by its manufacturer for business reasons, not pulled for a safety recall. Sermorelin's underlying pharmacology was FDA-reviewed during Geref's approval, giving it more regulatory history than CJC-1295 or ipamorelin, which have never been FDA-approved for any use.
Is CJC-1295 safer than sermorelin?
There's no controlled trial evidence to say so. CJC-1295, especially the DAC version, has a long 6-8 day half-life and no FDA oversight, versus sermorelin's shorter, more studied profile and FDA-reviewed history under the Geref brand. 'Safer' isn't established either way for CJC-1295.
What is tesamorelin actually approved for?
Tesamorelin (brand name Egrifta) is FDA-approved only for reducing excess abdominal fat in HIV patients with lipodystrophy, dosed at 2 mg subcutaneously daily. It is not approved for general fat loss, anti-aging, or use in people without HIV-associated lipodystrophy.
Why do people combine CJC-1295 and ipamorelin?
They act on two different receptors, GHRH receptor for CJC-1295 and the ghrelin receptor for ipamorelin, so some believe combining them produces a stronger GH pulse than either alone. That's a pharmacological theory, not a result confirmed by FDA-reviewed clinical trials in humans.
Can ipamorelin or CJC-1295 be legally prescribed by a doctor?
They're generally sold as 'research use only' chemicals rather than prescribed medications, because neither has FDA approval for human use. Some compounding pharmacies do prepare them under a prescription, but that differs from an FDA-approved drug pathway and carries less regulatory oversight.
How often do you inject sermorelin versus CJC-1295?
Sermorelin is typically injected daily, usually at bedtime, given its short 10-20 minute half-life. CJC-1295 without DAC needs similarly frequent dosing, but CJC-1295 with DAC can be dosed as infrequently as weekly because its albumin-binding component extends its half-life to roughly 6-8 days.
Does sermorelin raise IGF-1 levels?
Yes, when it successfully stimulates pituitary GH release, IGF-1 typically rises over weeks of use, which is why prescribers monitor IGF-1 labs to gauge response and avoid overdosing. The degree of rise is generally more moderate than with direct HGH injection.
Is tesamorelin more effective than sermorelin for fat loss?
They're not really comparable, because tesamorelin's FDA approval and trial data cover a specific population (HIV-associated lipodystrophy), while sermorelin has no FDA-reviewed fat-loss indication at all. Neither should be chosen for general fat loss based on the other's approved indication.
What are the main side effects across all four peptides?
Injection site reactions are common to all four. Tesamorelin's label specifically warns about elevated blood glucose and joint pain. Sermorelin's known effects include flushing and headache. CJC-1295 and ipamorelin side effect data rely mostly on user reports rather than monitored trials.
Where can sermorelin be obtained legally?
Through a licensed prescriber, usually via telehealth GH-therapy clinics or endocrinology practices, dispensed by a compounding pharmacy. See sermorelin peptide near me for how to find a legitimate prescribing and pharmacy pathway rather than an unregulated online seller.
Does insurance cover any of these peptides?
Tesamorelin (Egrifta) can be covered by insurance for its approved HIV lipodystrophy indication, subject to plan rules. Sermorelin, CJC-1295, and ipamorelin are generally not covered, since they're compounded or unapproved products used mostly off-label or outside FDA-approved indications.
Sources
- DailyMed, GEREF (sermorelin acetate) for injection, FDA label archive, NIH National Library of Medicine: Sermorelin was FDA-approved under the brand name Geref before being discontinued commercially
- Patchett SE et al., "Growth hormone-releasing hormone and its analogs in clinical use," PubMed PMID 8875383: Historical clinical use and adverse effect profile of sermorelin (GHRH 1-29) including injection site reactions, flushing, and headache
- FDA prescribing information, Egrifta (tesamorelin for injection), NDA 022505: Tesamorelin's FDA approval is limited to reduction of excess abdominal fat in HIV-associated lipodystrophy, dosed 2 mg daily, with glucose-related warnings
- Teichman SL et al., "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting growth hormone-releasing hormone analog," Journal of Clinical Endocrinology & Metabolism, PMID 16278266: Pharmacology and extended half-life (approximately 6-8 days) of CJC-1295 with DAC, and its non-approved status
- Raun K et al., "Ipamorelin, the first selective growth hormone secretagogue," European Journal of Endocrinology, PMID 9849822: Ipamorelin's mechanism as a selective ghrelin-receptor agonist with short half-life and reduced cortisol/prolactin effect compared to older secretagogues
- FDA, "Compounding and the FDA: Questions and Answers," FDA guidance on compounded drug oversight: FDA oversight concerns regarding manufacturing quality for compounded products versus FDA-approved manufacturing standards
- FDA, Warning Letter to a peptide marketing firm regarding unapproved new drugs, FDA Warning Letters database (example: CanaRx / peptide sellers cited under 21 U.S.C. 355): FDA enforcement actions against firms selling unapproved peptide products marketed with unproven human-use claims